When you see a Biotech putting out a lot of "news" that really isn't news...like enrollment numbers....its time to take caution. Too much so-called "news " is usually done by Biotechs to boost their stock price. Its Fluff. Run like heck.
Did he make this #$%$ up or is this a well known and used term?
it could be just a pull back for the next POP and not a full fib at this point. Keep in mind there are bag holders from when this stock was over $100. So they want their money back at some point.
Yes they really don't need a partner, but say a partner with an existing production line and world wide sales force with a great record came into the picture, the contract would have to be very economical for ACAD to sign it.
I am not worried or concerned one tad. ACAD really doesn't need a partner, they have a TON of CASH = 369 Million and NO DEBT. And could easily raise 150-200 MILLION more to go it alone. A Buy Out is gonna cost say...MRK about 5 Billion ( thats BILLION with a B ). So they will not enter into a deal without major DD. They might be waiting for the Alzheimer's data or after an accepted NDA
Type Value Conf.
resist. 30.10 2
resist. 28.78 2
resist. 25.34 3
resist. 24.88 2
resist. 23.75 5
resist. 22.44 3
resist. 21.24 9
supp 20.09 9
supp 19.24 3
supp 17.88 4
Look at the chart for the max time...you will see a TON of holders who bought at a way higher price than the present price. They want out. So anytime this stock hits a higher level it will get SOLD OFF FAST.
Yep smart. Especially considering there are a TON of BAG HOLDERS from the past that want to get their money back. They will sell it off when it pops like today.
The first time I read this it just looked like a hit piece, but where are the 5 patient results. Did they drop out for personal reasons, eg, did they move out of the area? Especially the 4 treated - If they were removed from the study WHY. If later you find out one or several had died or some other unknown issue then it could sink the stock, lead to a Black Box Warning or worse? Where are the results? I for one feel this concern is valid.
..." But Inovio's per-protocol analysis of the study's primary endpoint omits patients. How many patient are missing from the analysis? We don't know because Inovio didn't disclose. The study was designed to enroll 148 patients, according to a design schema on ClinicalTrials.gov, but Inovio could have enrolled more. If 148 patients were enrolled, Inovio's per protocol analysis omits five patients -- four treated with VGX-3100 and one patient on placebo.
Inovio did not disclose the more important intent-to-treat analysis of the study's primary endpoint. "
Found this article...OUCH!!! Inovio CEO Preps Retail Investors for Drug Study Failure
By: Adam Feuerstein
Inovio Pharmaceuticals (INO) CEO Joseph Kim is walking back expectations for the phase II study of its DNA vaccine VGX-3100 in women with high-grade cervical intraepithelial neoplasia (CIN 2/3), also known as cervical pre-cancerous lesions. Results from the VGX-3100 study should be announced any day, but I suspect Inovio already has data in hand. Why else would Kim be laying the foundation for a massive spin job, if not to cushion the vaccine's failure?
The red flags flying over Inovio are there for any clear-eyed investor to see:
Inovio pushed through shareholder vote approving a 1-for-4 reverse stock split on May 23, which went into effect on June 5. Why the need for a reverse stock split? Kim explained:
Our stockholders approved a reverse split to have our price and share structure reflect our leadership position in immunotherapies and expand our potential investor audience.
Interesting spin. Drug companies in leadership positions aren't generally valued with stock prices in the $2 range. More typically, terminally depressed stock prices -- like Inovio's -- are the direct result of management incompetence and/or drug development setbacks and failures. Innovio is very good at issuing press releases and promoting its stock to retail investors, but its track record of developing DNA vaccines is abysmal.
Actually the company fundamentals are OK for a small biotech. They have some rev's, no debt, low OS and some cash...so this tells me it is running on a good engine(management). They have NO PRODUCTS that i could find, so their Rev's are probably milestone payments from their partner. But here's your problem...they only have 2 Phase 2 trials and a ton of Phase 1's. So you are talking from 3-5+ years ( if you are lucky) away from anything close to a NDA. So for this it is already $10+ per share...to me this is somewhat over valued for a small biotech with no phase 3 trials. This is exactly the type of stock that could be $2 if you blink your eyes or $ 15 if it gets bought out. So its all about the technology, if you believe in the technology and the Partner Roche, then you will hang in there but it could be a long bumpy ride. Personally, I wouldn't hold your breath for a buy out. But I would love to see the results of any of the Phase 2 trials (When do you expect those to be completed ? ). Will the technology be validated?
One more little negative...there are a ton of bag holders over $10, ...they want their money back...so that will kill most big rally's - any major pop could be meet with a FULL FIB RETRACEMENT of 61% or even more. Keep that in mind.